By Chandrabhanu Singh Rayagada/Bhubaneswar, Sept. 3: The phase-3 clinical trial for India’s first Indigenous dengue vaccine, ‘DengiAll,’ commenced at the Kalinga Institute of Medical Sciences (KIMS) on Tuesday. This trial aims to evaluate the efficacy of the Indigenous tetravalent dengue vaccine developed by Panacea Biotec in collaboration with the Indian Council of Continue Reading
